Novo Nordisk's pre-market decline in US stocks narrowed to 20%, while Eli Lilly rose more than 10%

2024-12-20 19:12:55

Novo Nordisk's pre-market decline narrowed to 20%, after a sharp drop of nearly 30%, the largest single-day drop on record, due to the company's weight loss drug CagriSema trial results falling short of expectations. Eli Lilly's pre-market rise was more than 10%.

weight loss drug Novo Nordisk Lilly

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Trump says he doesn't care about bill
                            2025-11-19

                                    Supreme Court Pause on SNAP Benefits: Market Ripples, Policy Shock & Ticker Watch
                            2025-11-12

                                    After $2,000 Payments, Remaining Revenue to Slash National Debt
                            2025-11-16

                                    Trump Administration’s 50-Year Mortgage Gamble: What It Means for Housing, Builders and the Options Market
                            2025-11-12

                                    The Financial Times has reported that Oracle's, $ORCL, $300 billion OpenAI deal is already underwater
                            2025-11-19